The Gates Foundation’s new AI initiative: attempting to leapfrog global health inequalities?
By Jonathan Shaffer, Arsenii Alenichev, and Marlyn C. Faure,
BMJ Global Health
| 11. 03. 2023
The Bill & Melinda Gates Foundation has long been criticised for championing the trend of socially reductive, ‘magic bullet’ technical ‘solutions’ to the complex, historically shaped, politically conflicted problems at root of global health inequities.1–5 Their August 9th announcement of the launch of a new US$5 million, 48 project funding push6 to launch new ‘artificial intelligence (AI) large language models (LLM) in low-income and middle-income countries to improve the livelihood and well-being of communities globally’ is set to continue this hegemonic global health trend. And, as much as ‘magic bullets’ can solve issues, they, as bullets, are also capable of wounding and causing harm.
There are at least three reasons to believe that the unfettered imposition of these tools into already fragile and fragmented healthcare delivery systems risks doing far more harm than good.
We are not Luddites. New tools of technology, biomedicine, scientific knowledge and population care have often made life better and safer for those with access and control over their use.7 LLMs and AI, however, will not be so equity-advancing despite the Gates Foundation’s overheated...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...